In another retrospective non-US study (at the Shanghai Chest Hospital), median OS was not reached for 115 patients with advanced NSCLC (both nonsquamous and squamous), PD-L1 ≥50%, and no EGFR or ALK genomic alterations who received first-line pembrolizumab-chemotherapy (33). Here, EGFR is linked to non-small cell lung carcinoma.